105 filings
8-K
RGRXD
Regenerx Biopharmaceuticals Inc
7 Aug 23
Submission of Matters to a Vote of Security Holders
3:57pm
8-K
RGRXD
Regenerx Biopharmaceuticals Inc
10 Jul 23
Entry into a Material Definitive Agreement
5:19pm
8-K
RGRXD
Regenerx Biopharmaceuticals Inc
20 Jun 23
Entry into a Material Definitive Agreement
5:38pm
8-K
RGRXD
Regenerx Biopharmaceuticals Inc
15 Nov 21
2021 Annual Stockholders Meeting
2:55pm
8-K
RGRXD
Regenerx Biopharmaceuticals Inc
22 Jul 21
Regulation FD Disclosure
5:00pm
8-K
0p4 sqiec51
1 Jul 21
Entry into a Material Definitive Agreement
3:43pm
8-K
i1a46almw7zyt
14 May 21
RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome
3:07pm
8-K
mmgy4o g14
19 Mar 21
RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial
12:55pm
8-K
4et9qg4s
21 Oct 20
Entry into a Material Definitive Agreement
4:19pm
8-K
kw6aq38bndh9un pzvc
13 Oct 20
RegeneRx Expects to Complete Short-Term Financing While Awaiting Completion of Phase 3 Clinical Trial for Dry Eye Syndrome
7:00am
8-K
8cdu0k7t
30 Sep 19
Submission of Matters to a Vote of Security Holders
5:00pm
8-K
n3sprinuupwooo8
5 Mar 19
Entry into a Material Definitive Agreement
4:53pm
8-K
2oafzt9t4hr2wmon mu1
15 Jun 18
Submission of Matters to a Vote of Security Holders
3:50pm
8-K
5njw97e
25 Apr 18
Other Events
4:29pm
8-K
newrth
2 Mar 18
RegeneRx Secures $1 Million in Funding
12:00am
8-K
7ad1vkmzu7oq
31 Aug 17
RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia
12:00am
8-K
oklxt 1b5
13 Mar 17
Regulation FD Disclosure
12:00am
8-K
4toxr
2 Nov 16
Submission of Matters to a Vote of Security Holders
12:00am
8-K
9qykylfu192a w0sq6
12 Sep 16
Rodman & Renshaw 18 th Annual Global Investment Conference September 2016
12:00am
8-K
mznr6zqpaa2mkocczzb
1 Jul 16
RegeneRx Announces $1.75 Million Private Placement
12:00am